45 withdrawn. 45 Phase 2, 16 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 45 | Withdrawn 45 |
| Phase 1 | 16 | Withdrawn 16 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms ASTX029, ASTX727 - Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-01-31 | 2026-02-13 | |
| A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis Ruxolitinib, INCB57643 - Myelofibrosis | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-09-11 | 2025-05-22 | |
| Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms Captopril - Bone Marrow Fibrosis, Myeloproliferative Neoplasm | Phase 1 / Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2024-04-01 | 2023-10-11 | |
| A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia). KER-047 - Iron Deficiency Anemia | Phase 2 | Withdrawn | Keros Therapeutics, Inc. | 2023-11-30 | 2023-11-24 | |
| A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies Fludarabine + Total Marrow Irradiation - Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Naoyuki G. Saito, M.D., Ph.D. | 2023-10-01 | 2023-12-11 | |
| CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation - Hematologic Diseases, Hematologic Malignancy | Phase 2 | Withdrawn | Baptist Health South Florida | 2022-09-01 | 2022-09-27 | |
| A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN zelavespib - Accelerated Phase MPN, Blast Phase MPN | Phase 2 | Withdrawn | Samus Therapeutics, Inc. | 2022-06-15 | 2022-11-10 | |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2021-06-01 | 2021-06-30 | |
| A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy APG-1252, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Withdrawn | Ascentage Pharma Group Inc. | 2020-12-15 | 2022-07-12 | |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis LOXL2 Inhibitor PAT-1251, Quality-of-Life Assessment, Questionnaire Administration - Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-07-24 | 2019-08-13 | |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Laboratory Biomarker Analysis, Placebo - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission | Phase 2 | Withdrawn | City of Hope Medical Center | 2018-12-01 | 2018-11-21 | |
| A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Nilotinib, Ruxolitinib - Leukemia, Chronic Myeloid | Phase 1 / Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2018-01-01 | 2021-02-16 | |
| Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS BP1001 (varying dose), BP1001 (fixed dose), Dasatinib - Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Bio-Path Holdings, Inc. | 2017-09-01 | 2020-05-28 | |
| StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies Unmanipulated UCB, SR-1 UCB - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2017-04-01 | 2017-12-05 | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant T Regulatory cells, Fludarabine, Cyclophosphamide - Hematologic Malignancies | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2016-06-01 | 2017-12-02 | |
| A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis Pacritinib - Primary Myelofibrosis | Phase 2 | Withdrawn | Baxalta now part of Shire | 2015-11-30 | 2021-05-05 | |
| Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia BL-8040 - Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Sheba Medical Center | 2014-11-01 | 2016-08-15 | |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies Treg cells, CD3+ Teff cells, Fludarabine - Hematologic Malignancy, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2014-01-01 | 2017-12-02 |
Showing 20 of 45. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (21) · Leukemia, Myeloid, Acute (18) · Myelodysplastic Syndromes (16) · Leukemia (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Primary Myelofibrosis (12) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Leukemia, Myeloid, Chronic-Phase (10) · Lymphoma, Non-Hodgkin (9) · Congenital Abnormalities (8) · Leukemia, Myeloid, Accelerated Phase (8) · Blast Crisis (7) · Hodgkin Disease (7) · Lymphoma, B-Cell, Marginal Zone (7)
Hemic and Lymphatic Diseases (45) · Bone Marrow Diseases (44) · Hematologic Diseases (42) · Neoplasms (36) · Leukemia, Myeloid (34) · Neoplasms by Histologic Type (34) · Chronic Disease (31) · Disease Attributes (31) · Pathologic Processes (31) · Pathological Conditions, Signs and Symptoms (31) · Leukemia (21) · Immune System Diseases (19) · Immunoproliferative Disorders (18) · Lymphatic Diseases (18)
Cyclophosphamide (9) · Peripheral Blood Stem Cell Transplantation (9) · fludarabine phosphate (8) · Busulfan (6) · Cyclosporine (6) · Cytarabine (6) · Methotrexate (6) · Whole-Body Irradiation (5) · Tacrolimus (4) · fludarabine (4) · Filgrastim (3) · Idarubicin (3) · Imatinib Mesylate (3) · Mycophenolic Acid (3) · Radiotherapy (3)
M.D. Anderson Cancer Center (6) · Masonic Cancer Center, University of Minnesota (3) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · Hadassah Medical Organization (2) · Rush University Medical Center (2) · University of Michigan Rogel Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Ascentage Pharma Group Inc. (1) · Baptist Health South Florida (1) · Baxalta now part of Shire (1) · Bio-Path Holdings, Inc. (1) · Bristol-Myers Squibb (1) · Case Comprehensive Cancer Center (1) · Columbia University (1)
United States (24) · Israel (4) · Australia (1) · Germany (1) · Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · Russia (1) · United Kingdom (1)
Claudio Brunstein, MD, PhD (2) · Philip D. Bonomi, MD (2) · Aaron Gerds, MD (1) · Aref Al-Kali, M.D. (1) · Arnon Nagler, MD (1) · Bruno de Medeiros (1) · Chetan Jeurkar, DO (1) · Dale Bixby, M.D., Ph.D. (1) · Deborah A. Thomas, MD (1) · Gary J. Schiller, MD (1) · Guenther Koehne, MD (1) · Guillermo Montalban Bravo (1) · Gwen L. Nichols, MD (1) · H. Joachim Deeg, MD (1)
P01CA075606 (2), P01CA065493 (1), P01CA108671 (1), P30CA016672 (1), P30CA036727 (1), P30CA072720 (1)